The evolution of kidney tumours

Some very interesting work has been coming out of the Francis Crick Institute in London about the evolution of kidney tumours. The research is being led by Dr Samra Turajlic who also works at the Royal Marsden Hospital in London and is one of KCSN’s trustees. Here is her explanation of this very exciting work: […]

read more

Molecular genetics of renal cell carcinoma

Most renal cell carcinomas (RCC) are diagnosed from studying the cells from a biopsy under a microscope (histology findings), with and without the use of antibodies to check for certain proteins in the tumour tissue (immunohistochemical examination). RCC tumours are very heterogeneous – there are many subtypes of RCC which have different appearances under the […]

read more

The most complete catalogue of clear cell renal cell carcinoma (ccRCC)

Researchers at the University of Texas (UT) Southwestern Medical Center have developed what could be the most complete catalogue of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer. This cancer is very diverse in character (heterogenous) and there is high variability in tumours. This heterogeneity makes is difficult to diagnose […]

read more

ASCO GU 2019: When to obtain genetic testing for renal cell carcinoma

The following paper was presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Brian Shuch provided a summary and guide to genetic testing for syndromic renal cell carcinoma (RCC). There is an established strong inheritance pattern in kidney cancer, and now there are 15+ recognised […]

read more

Kidney cancer may begin to develop in childhood

Scientists working on a Cancer Research UK funded study have discovered that the development of kidney cancer follows distinct paths, which can begin in childhood. These evolutionary paths enable scientists to detect whether a tumour will be aggressive and spread. “We could use these rules to help choose the best treatments, and potentially to diagnose some […]

read more

Update on papillary kidney cancer

The following is an interview with Dr Ramaprasad Srinivasan, Head of the Molecular Cancer Section at the National Cancer Institute, Bethesda, USA. Dr Srinivasan talks about the genetics of type 1 and type 2 papillary kidney cancer, including the results from the CREATE trial with crizotinib, which was presented at the American Society of Clinical Oncology Genitourinary […]

read more

Implications of the complex genomic landscape of RCC for targeted therapy and immunotherapy

This article discusses the multiple gene changes (genetic heterogeneity) found in renal cell carcinoma (RCC) and its potential effect on treatment options and effectiveness of drugs for advanced RCC. The study identifies some gene changes (mutations), which may contribute to progression of RCC and the relatively poor efficacy of current drug treatment options. The article […]

read more
Showing all 7 results
  TOP